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Background:Observational studies favor percutaneous closure of patent foramen ovale (PFO) over medical treat-
ment to reduce recurrent strokewhile randomized trials fail to demonstrate signiﬁcant superiority of percutane-
ous PFO closure. Few long-term studies are available post PFO closure. This study reports long-term clinical
outcomes after percutaneous PFO closure.
Methods: Between 1997 and 2006, 86 consecutive eligible patients with cerebrovascular events, presumably re-
lated to PFO, underwent percutaneous PFO closure. All 86 patients were invited to a long-term follow-up, which
was carried out during 2011 and 2012.
Results: Percutaneous PFO closurewas successfully performed in 85 of 86 patients. The follow-up ratewas 100%. No
cardiovascular or cerebrovascular deaths occurred. Two patients (both women) died from lung cancer during
follow-up. Follow-up visits were conducted for 64 patients and the remaining 20 patients were followed up by
phone. Themean follow-up timewas 7.3 years (5 to 12.4 years).Meanage at PFO closurewas 49 years. Onepatient
had a minor stroke one month after PFO closure and a transient ischemic attack (TIA) two years afterwards. One
other patient suffered from a TIA six years after closure. No long-term device-related complications were observed.
Conclusions: Percutaneous PFO closure was associatedwith very low risk of recurrent stroke and is suitable inmost
patients. We observed no mortality and no long-term device-related complications related to PFO closure, indicat-
ing that percutaneous PFO closure is a safe and efﬁcient treatment even in the long term.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
A patent foramen ovale (PFO) is a common heart defect and is pres-
ent in about 25% of the general population [1].
An association between PFO and cryptogenic stroke (CS) in young
adults has been shown in several studies. Furthermore, a relationship
between increased risk for recurrent thromboembolic events, PFO and
CS has previously been reported [2–5]. PFO and atrial septal aneurysm
(ASA) have been reported to be associated with an increased risk of
recurrent thromboembolic stroke, and a large PFO is a predictor for
cerebrovascular ischemic events [6–9]. Potential therapeutic strategiesstudy was supported by the
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land Ltd.Open access under CC BY-NCfor secondary prevention of paradoxical embolic stroke include long-
term oral anticoagulation or antiplatelet medication, surgical PFO clo-
sure, and percutaneous PFO closure with a catheter-based procedure
using a septal occluder device. Percutaneous PFO closure has been
shown to be safe and feasible [10–13]. Several different devices and dif-
ferent regimens of antiplatelet or anticoagulant therapy are used at
present. Five observational trials have indicated that PFO closure by
device lowers the relative risk of recurrent cerebrovascular events by al-
most 80% compared to medical treatment [14–18]. In addition, three
randomized trials (CLOSURE I, RESPECT and the PC Trial) have thus far
been published [19–21]. CLOSURE I showed no signiﬁcant beneﬁt of de-
vice closure over medical therapy during two years of follow-up. The
primary outcomes of the most recent trials, RESPECT and the PC Trial,
were not signiﬁcantly affected by which treatment was given. There
are few studies reporting long-term clinical outcomes of device closure
and, given the relatively low yearly rate of recurrent stroke (1–2%)
[22,23], there is a need for much larger follow-up studies, either by
recruiting more patients or by maintaining a longer follow-up period.
The number of patients lost to follow-up has to be kept to a minimum,
especiallywhen the event rate is low, to avoid givingmisleading results.
The aim of the present study was to provide a long-term clinical follow-
up of patients with a previous percutaneous closure of their PFO as sec-
ondary prevention after a cryptogenic stroke, by monitoring survival,
complications, recurrent stroke and other clinical signiﬁcant conditions.-ND license.
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2.1. Patient selection
Between 1997 and 2006, 86 consecutive patients (47 men and 39 women) were re-
ferred to our center for PFO closure. All these patients were diagnosed with cryptogenic
stroke or transient ischemic attack (TIA) associated with PFO by neurologists and cardiol-
ogists at local hospitals before theywere referred. Patients were referred from hospitals in
central and western part of Sweden. Due to the complexity of cryptogenic stroke and PFO,
further evaluation of the patient's clinical data andmedical records, including transesoph-
ageal echocardiography (TEE), computerized tomography (CT) scan or magnetic reso-
nance imaging (MRI) of the brain, was made by our interventional cardiologists, who
took the ﬁnal decision about PFO closure after consulting the TEE imaging expert and
stroke expert.
For both index stroke/TIA and at followup, a diagnosis of TIAwas given by the treating
neurologist if acute neurological deﬁcits with a probable vascular (ischemic) cause
completely resolved within 24 h. Ischemic stroke was deﬁned as a sudden new focal neu-
rological deﬁcit lasting more than 24 h [24]. Stroke etiology was deﬁned according to the
modiﬁed TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria [25].
Patients with stroke of known origin, such as cardiac events (atrial ﬁbrillation (AF),
acute myocardial infarction within the previous four weeks, or large apical infarction at
any time), patientswithout PFO, and patientswithmajor aortic plaques, aswell as patients
with decompression illness or orthodeoxia–platypnea, were excluded from the study. If
other probable causes of stroke (as described above) had been ruled out by adequate im-
aging and biochemical testing, the cerebrovascular event was considered cryptogenic and
related to PFO if the presence of a PFO with or without ASA was established.
The main criteria for closure were patients with at least one cryptogenic stroke with
high-risk morphology (PFO with ASA) or recurrent cryptogenic stroke and a PFO without
ASA.
The present study was approved by the regional ethics review board in Gothenburg,
Sweden and all patients gave written informed consent.2.2. PFO closure
Closure of the PFO guided by a perioperative TEE was performed under general
anesthesia and the Amplatzer® PFO Occluder device (AGA Medical Corp, Plym-
outh, MN, USA) was used in all patients who underwent PFO closure. Right-to-
left shunting, at rest or during the Valsalva maneuver, was detected in all patients
by TEE before the PFO closure.
Intraprocedural catheter-related complications were deﬁned according to Khairy
et al. [26]. Major complications were deﬁned as death, hemorrhage requiring blood
transfusion, cardiac tamponade needing surgical intervention, and massive fatal pul-
monary emboli. Minor complications were deﬁned as bleeding not requiring transfu-
sion, periprocedural atrial arrhythmias, transient atrioventricular node block, device
arm fractures, device embolization with successful catheter retrieval, asymptomatic
device thrombosis, need for recatheterization, symptomatic air embolism, transient
ST-segment elevation, arteriovenous ﬁstula formation, and femoral hematoma.2.3. Follow-up
All patients were examined six months after PFO closure by the interventional cardi-
ologist to assess periprocedural complications and clinical status. A TEE was also per-
formed at six months after PFO closure with color Doppler and contrast injections
during the Valsalva maneuver in all patients. TEE was repeated every six months in pa-
tients with residual substantial shunting. Residual shunting was deﬁned as small when
1–20 bubbles were seen in the left atrium or when the shunt was seen only with color
Doppler, despite multiple contrast injections during the Valsalva maneuver. When more
than 20 bubbles were seen in the left atrium, the shunt was considered substantial [27].
Patients with residual shunting continued with anticoagulation treatment until com-
plete closure of PFO occurred. After six months, no routine follow-up was carried out by
our unit; follow-up was entirely left to the referring physician. No recommendations re-
garding medical treatment were made at the time of our termination of follow-up.
During 2011 and2012, all surviving patientswere invited to long-term clinical follow-
up and personal interviews. A structured medical history including items on recurrent
stroke/TIA, risk factors for stroke and potential complications to percutaneous treatment
was obtained for all patients. Patients who agreed to attend follow-up at our center
were examined with electrocardiogram (ECG) and transthoracic echocardiography
(TTE). The patient's neurological status was assessed using the modiﬁed Rankin Scale
[28–30]. Patients who could not attend our center were followed up with a structured
telephone interview. No patient refused follow-up.
Information about recurrent stroke/TIA was obtained from medical records of
patients if they were admitted at any hospital for a new clinical event of ischemic
stroke or TIA after PFO closure. Informed consent was given by all patients for
access to their medical records from all clinics where they had been treated during
the follow-up for suspect events. All relevant medical records and documentation
of imaging procedures were collected.
Vital statuswas ascertained fromhospital records, public civil registries and the Swed-
ish Cause of Death Register (CDR) [31]. Information on the two patientswho had dieddur-
ing follow-up was obtained from hospital records.2.4. Statistical analysis
Distributions are presented as mean and standard error of the mean. Event-free sur-
vival was displayed by a Kaplan–Meier plot. Statistical analyses were performed using
PASW Statistics forWindows, Version 18.0 software (IBMCorporation, Armonk, NY, USA).
3. Results
No patients died from cardiovascular causes. Two patients died of
lung cancer at 39 and 60 months after PFO closure, respectively. Both
of these patients were free from recurrent events before death.
The long-term follow-up was successfully performed in all the 84
live patients (follow-up rate 100%). Sixty-four patients attended the
follow-up visit. Twenty patients did not attend but were followed up
by a structured telephone interview and retrieval of hospital records.
Fourteen of these patients were living far away from our site and six
patients lived nearby but were unwilling to come to the clinic for an
examination. The follow-up was performed within a mean of
7.3 years (minimum 5.0 years – maximum 12.4 years) after the
PFO closure, corresponding to an accumulated follow-up of 616 pa-
tient years. The mean follow-up after the index stroke or TIA event
was 13 years (range: 6–20 years).
Prior to closure, 68 patients in this study (79%) had CT or MR data
corresponding to the current stroke or TIA symptoms before closure.
Sixty-one patients (71%) had PFO with ASA and 25 patients (29%) had
PFO without ASA. Forty-eight patients (56%) had ﬁrst-time stroke/TIA
while 38 (44%) had recurrent stroke/TIA. Further information on patient
characteristics andmedication at closure and at follow-up are displayed
in Table 1.
PFO closurewith anAmplatzer devicewas performed successfully in
85 of 86 patients. One patient with several septal defects was not suit-
able for percutaneous closure and remained on lifelong treatment
with warfarin. Fig. 1 shows indications for PFO closure in this study.
Mean age at PFO closure was 49 years and at follow-up 56 years. No
cardiovascular or cerebrovascular deaths related to the device closure
occurred. At the time of the index event, 61 of the patients had a PFO
with ASA. One patientwith a signiﬁcant carotid stenosis was considered
by the neurologists to have a high risk of paradoxical embolism and the
index event was considered to be caused by fragmented thrombus;
therefore, the patient underwent closure. This patient was event free
at follow-up and the carotid stenosis was not of any clinical relevance;
therefore, the patient was not operated on but only medicated with
75 mg acetylsalicylic acid.
ScoringMRS at follow-up, 78 patients (90%) had a goodMRS score of
0–1 (0 = no symptoms at all; 1 = no signiﬁcant disability despite
symptoms, able to carry out all usual duties and activities). Six patients
(8%) scored 2–3 (2 = slightly disability, unable to carry out all previous
activities, but able to look after own affairs; 3 = moderate disability re-
quiring some help, but able to walk without assistance).
3.1. Recurrent stroke or TIA
In this long-term study, two patients (2%) suffered from a recurrent
neurologic event, giving a rate of three neurological events per 1000
patient-years (PY). Of the two patients with recurrent events, one pa-
tient reported having severe migraine headache preoperatively and
she suffered an MRI-veriﬁed ischemic stroke one month after PFO clo-
sure at the age of 36. However, the same patient suffered a TIA (without
CT orMRI evidence of new cerebral lesions) two years after closure. The
other patient suffered a TIA (without CT or MRI evidence of new cere-
bral lesions) six years after closure. He had cardiovascular risk factors
including age (72 years at the time of the recurrent event), hyperten-
sion, and an elevated BMI of 28. Both neurological events occurred in
patients who had undergone successful PFO closure and had no evi-
dence of thrombus formation or residual leaking during the follow-up.
They had PFO and ASA before closure and complete PFO closure was
Table 1
Patient characteristics and medication at closure and at follow-up.
Characteristics No. (%) of patients
At closure (n = 86) At long-term follow-up (n = 84)
Age (range) 49 ± 10.6 56 ± 10.44
Hypertension 15 (17) 20 (23)
Hyperlipidemia 15 (17) 22 (26)
Diabetes Mellitus 2 (2) 2 (2)
Atrial ﬁbrillation 0 (0) 0 (0)
PVD 1 (1) 1 (1)
Current smoker 11 (13) 9 (11)
Medication
Warfarin 55 (64) 2 (2)
Aspirin 25 (29) 46 (54)
Clopidogrel 1 (1) 0 (0)
Dipyridamol/+ 4 (5) 2 (2)
Dipyridamol 0 1 (1)
No medication 0 33 (38)
PFO: patent foramen ovale, PVD: peripheral vascular disease.
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75 mg acetylsalicylic acid at the time of recurrence. One patient with
brain abscess and PFOwas included in this study because the panel con-
sidered the event assuredly related to PFO. This patient had no more
events during the time of follow-up.
Long-term event-free survival post PFO closure is shown in Fig. 2.
No device-related or medical treatment-related complications were
noticed in these two patients at the time of follow-up. Regarding the
medication, as shown in Table 1, all 86 patients (100%)were onmedical
treatment, of whom55 (64%)were onwarfarin and 25 (29%) on acetylic
acid. At long-term follow-up, only 51 (57%)were onmedical treatment,
of whom only two (2%) on warfarin and 46 (54%) on acetylic acid.
3.2. Complications
There were no procedure-related major complications during the
implantation of the closure device. One patient with several septal de-
fects was not suitable for percutaneous closure. Three patients (3.5%)
suffered from AF during the ﬁrst six months after PFO closure and this
was converted to sinus rhythm by electrical cardioversion. One of
these patients was still in AF at the six-month follow-up, but it was in
due course converted such that the patient was in sinus rhythm atFig. 1. Indication for percutaneous closure of patent foramen ovale (PFO) in 86 patients:
1 = at least one previous cryptogenic stroke (CS) + atrial septal aneurysm (ASA);
2 = two previous CS without ASA; 3 = one CS with activated protein C resistance;
4 = one CS without ASA but huge right to left passage; 5 = only one CS without ASA;
6 = brain abscess + PFO.long-term follow-up. No further hospitalization was reported and this
patient had no recurrent events.
No long-term complications related to PFO closure, such as death,
device embolization, or chronic AF were found.
3.3. Echocardiographic follow-up
After a mean period of six months, the TEE showed complete device
closure in 88% of patients. Eight patients (10%) showed a small shunt
and two patients (2%) showed a substantial shunt. After 18 months,
only six patients (7%) still showed small shunts and none showed sub-
stantial shunts. No device thrombus or device embolization was detect-
ed. At the long-term follow-up visit, a transthoracic echocardiography
(TTE) was performed on 64 patients (74%) and no residual shunts
were detected with color Doppler. No long-term device-related compli-
cations of PFO closure were observed.
3.4. Other observed events
AV block: One patient with PFO and ASA underwent PFO closure in
May 2005 with a 35 mm Amplatzer device, and a pacemaker was
inserted due to AV block III in December 2010 at the age of 70. One
other patient who underwent PFO closure, also with a 35 mm
Amplatzer device, at the age of 37 suffered AV block I and periodic AV
block II (Wenckebach periodicity), which was observed at several hos-
pital visits. This AV block I and II was asymptomatic and the patient
had AV block I at time of long-term follow-up.
Migraine: 31% of patients reportedmigraine headache preoperative-
ly, which reduced to 13% at follow-up. However, the aim of this study
was not to investigate the prevalence of migraine headache, so this ret-
rospective ﬁnding represents only patient recall.
4. Discussion
PFO closure in this long-term follow-up study of up to 12.4 years
was associated with a very low recurrent event rate of 0.3% per year
and a success rate of 99%. The 0.3% per year rate of recurrent neurolog-
ical events in this study is lower than reported in a recently published
meta-analysis of 48 studies, which showed a recurrence rate of 0.8%
per year for PFO closure and 5% per year for pharmacologically treated
PFO patients [32]. The rate of recurrent stroke/TIA in this study is essen-
tially based on patient-reported events, as in the CLOSURE I andCases
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Fig. 2. Event-free survival post PFO closure.
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judged to be caused by cerebral ischemia. In order to study recurrent
events accurately, we requisitioned patient records from the respective
hospitals for patients with symptoms suggestive of recurrent events.
There are three randomized clinical trials on device PFO closure to
date. The ﬁrst study, CLOSURE I, showed no signiﬁcant beneﬁt of PFO
closure on the primary end point to prevent recurrent stroke but had
a trend towards a slight reduction in recurring TIAs: 3.3% for PFO closure
vs. 4.6% for medical therapy alone [19]. The RESPECT trial [20] and the
PC Trial [21] have both been published recently and, as with the
CLOSURE I study, their primary outcome was not signiﬁcantly affected
by which treatment was given. However, the results of these studies
should be interpreted with caution because the event rate was lower
than expected. Recruitment to the studies was very difﬁcult and took
more than eight years to accomplish; in the meantime, very large num-
bers of PFOs were closed off-label, which may lead to selection bias by
excluding high-risk PFO patients. Furthermore, the high dropout rate
compared to event rate in these studies makes interpretation of the
intention-to-treat analysis of recurrence rate susceptible to error. The
low recurrence rate of 0.3% per year in the present study is most likely
explained by patient selection; we excluded patients with PFO and
stroke that was not considered to be cryptogenic, due to the presence
of ischemic heart disease, AF, arterial plaque or atypical neurologic
symptoms. Approximately 30% of our referrals are accepted for PFO clo-
sure. Given the clear positive effects seen in observational studies
[14–18], randomized trials of adequate size are urgently needed.
The present study provides true long-term follow-up and adds to
our understanding of the long-term consequences of PFO closure in pa-
tients with a history of cerebrovascular events associated with PFO. The
mean follow-up post PFO closure was 7.3 years, with a maximum of
12.4 years, and the mean time from index event to follow-up was
13 years. This is the ﬁrst long-term clinical follow-up of PFO patients
with a follow-up rate of 100%, and where the majority of patients seen
at clinic visits were given a clinical examination including an echocar-
diogram. Two earlier studies have reported comparable follow-up pe-
riods but both had a lower follow-up rate. The mean follow-up in the
study by Fischer et al. was 15.4 years but follow-up rate was only 89%
post PFO closure [22]. The mean follow-up after index event in the
study by Wahl et al. was 10 years with a mean follow-up rate of 98%
[23]. When the event rate is low it is of high importance to have a
high follow-up rate in order to eliminate the risk of bias.
Therewere noprocedure-relatedmajor complications in thepresent
study. The 3.5% incidence of AF was the only potentially procedure-
relatedminor complication in the present study. However, the observed
AF was transient and no chronic AF could be observed. The incidence of
AF varies in other studies from0.6% [33] to 7.6% [34] during theﬁrst year
post PFO closure. In 2003, Khairy et al. reported 7.9% major complica-
tions and 1.5%minor complications [26] and in 2009Wahl et al. report-
ed a complication rate of 0.8% [33]. The reduction of complication rate
over time ismost likely a result of better patient selection, better devices
and greater experience among interventional cardiologists, although
the retrospective approach in the present paper might underestimate
minor complications, such as minor bleeds.
PFO closurewith the Amplatzer device has been reported to be asso-
ciated with lower risk of device thrombus formation compared to other
PFO occluding devices [35]. We found no thrombus formation on the
Amplatzer occluder device.
In the present study,we had an 88% success rate for PFO closurewith
the Amplatzer device at six-month follow-up and 93% after a mean
follow-up of 18 months, compared to 86.1% at six months and 86.7 at
24 months in the CLOSURE I study, which used the STARFlex device
[19]. Minimal shunting observed in six patients (7%) in our study after
18 months was not considered to be of any clinical relevance and was
not associated with recurrent events. Neither of the patients who had
recurrent stroke nor TIA (2%) had any detectable residual shunting. No
shunts were detected by TTE in the long-term follow-up.The results of this study should be considered in the light of the fol-
lowing limitations. First, the diagnosis of paradoxical embolism remains
presumptive and cannot be considered synonymous with cryptogenic
stroke or TIA. Second, the patient population in this study is a selected
group referred to our hospital in a non-randomized, retrospective, enti-
tled order, without a control group, as in most case studies. Due to the
lack of widely accepted guidelines on themanagement of PFO and cryp-
togenic stroke, 53% of patients in this study had discontinued theirmed-
ical treatment (in agreement with their physicians). However, despite
discontinuation of medical therapy, we did not observe more than 2%
recurrent events.
5. Conclusions
In this long-term follow-up study of consecutive patients, percuta-
neous closure of PFO was associated with very low risk of recurrent
stroke, no mortality related to cerebrovascular disease, and no short-
or long-term device-related major complications, thus indicating that
percutaneous PFO closure is a safe and efﬁcient treatment option. None-
theless, long-term randomized studies are needed to determine the ef-
ﬁcacy of different therapeutic measures and the importance of patient
selection.
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